MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen

MaxCyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded MaxCyte from “hold” to “buy,” though analyst opinions remain mixed and MarketBeat’s consensus rating is “hold,” with a $4.50 consensus price target.
  • MaxCyte reported quarterly loss per share of $0.05, better than the $0.08 loss analysts expected, and revenue of $8.16 million versus a $7.39 million estimate.
  • CEO Maher Masoud bought 100,000 shares for $121,000, increasing his direct holdings by 21.05%.
  • MarketBeat previews the top five stocks to own by December 1st.

MaxCyte (NASDAQ:MXCT - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the stock. Weiss Ratings cut shares of MaxCyte from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, November 4th. BTIG Research reiterated a "neutral" rating on shares of MaxCyte in a research report on Monday, August 24th. Finally, Stifel Nicolaus set a $4.00 price target on MaxCyte in a research note on Thursday, November 12th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, MaxCyte has a consensus rating of "Hold" and a consensus target price of $4.50.

Read Our Latest Analysis on MXCT

MaxCyte Stock Up 7.4%

NASDAQ:MXCT opened at $1.38 on Friday. MaxCyte has a 52 week low of $0.64 and a 52 week high of $1.80. The firm's 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.08.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03. The business had revenue of $8.16 million during the quarter, compared to analysts' expectations of $7.39 million. MaxCyte had a negative net margin of 81.40% and a negative return on equity of 15.05%. Research analysts expect that MaxCyte will post -0.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Maher Masoud purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The stock was acquired at an average price of $1.21 per share, with a total value of $121,000.00. Following the completion of the purchase, the chief executive officer directly owned 575,000 shares in the company, valued at $695,750. This trade represents a 21.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MaxCyte

A number of large investors have recently bought and sold shares of the company. Canada Pension Plan Investment Board bought a new stake in shares of MaxCyte during the 2nd quarter worth approximately $44,000. Public Employees Retirement System of Ohio acquired a new stake in shares of MaxCyte during the 2nd quarter worth approximately $54,000. Empowered Funds LLC bought a new position in MaxCyte in the third quarter valued at approximately $66,000. Bank of America Corp DE increased its stake in MaxCyte by 30.1% in the first quarter. Bank of America Corp DE now owns 127,258 shares of the company's stock valued at $89,000 after acquiring an additional 29,457 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in MaxCyte in the second quarter valued at approximately $99,000. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

(Get Free Report)

MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company's offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MaxCyte Right Now?

Before you consider MaxCyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.

While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines